These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 31660310)

  • 1. Current status of oral anticoagulant reversal strategies: a review.
    Rawal A; Ardeshna D; Minhas S; Cave B; Ibeguogu U; Khouzam R
    Ann Transl Med; 2019 Sep; 7(17):411. PubMed ID: 31660310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal strategies in patients treated with direct oral anticoagulants.
    Gressenberger P
    Vasa; 2019 Aug; 48(5):389-392. PubMed ID: 30719950
    [No Abstract]   [Full Text] [Related]  

  • 3. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents.
    Kaide CG; Gulseth MP
    J Emerg Med; 2020 Feb; 58(2):217-233. PubMed ID: 31831187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct (New) Oral Anticoagulants (DOACs): Drawbacks, Bleeding and Reversal.
    Karcioglu O; Zengin S; Ozkaya B; Ersan E; Yilmaz S; Afacan G; Abuska D; Hosseinzadeh M; Yeniocak S
    Cardiovasc Hematol Agents Med Chem; 2022; 20(2):103-113. PubMed ID: 34521332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct oral anticoagulants: a review on the current role and scope of reversal agents.
    Chaudhary R; Sharma T; Garg J; Sukhi A; Bliden K; Tantry U; Turagam M; Lakkireddy D; Gurbel P
    J Thromb Thrombolysis; 2020 Feb; 49(2):271-286. PubMed ID: 31512202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Direct oral anticoagulant associated bleeding].
    Godier A; Martin AC; Rosencher N; Susen S
    J Mal Vasc; 2016 Jul; 41(4):272-8. PubMed ID: 27297642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA).
    Rogers KC; Finks SW
    Am J Med; 2019 Jan; 132(1):38-41. PubMed ID: 30053385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological reversal of the direct oral anticoagulants-A comprehensive review of the literature.
    Shaw JR; Siegal DM
    Res Pract Thromb Haemost; 2018 Apr; 2(2):251-265. PubMed ID: 30046727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Relevance of Preclinical and Clinical Studies of Four-Factor Prothrombin Complex Concentrate for Treatment of Bleeding Related to Direct Oral Anticoagulants.
    Sarode R; Welsby IJ; Hoffman M
    Ann Emerg Med; 2023 Sep; 82(3):341-361. PubMed ID: 37204347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal.
    Brown KS; Zahir H; Grosso MA; Lanz HJ; Mercuri MF; Levy JH
    Crit Care; 2016 Sep; 20(1):273. PubMed ID: 27659071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists.
    Desai NR; Cornutt D
    Hosp Pract (1995); 2019 Aug; 47(3):113-122. PubMed ID: 31317796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists.
    Rodriguez V; Stanek J; Kerlin BA; Dunn AL
    Clin Appl Thromb Hemost; 2022; 28():10760296221078842. PubMed ID: 35275498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversing factor Xa inhibitors - clinical utility of andexanet alfa.
    Kaatz S; Bhansali H; Gibbs J; Lavender R; Mahan CE; Paje DG
    J Blood Med; 2017; 8():141-149. PubMed ID: 28979172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding.
    Grottke O; Afshari A; Ahmed A; Arnaoutoglou E; Bolliger D; Fenger-Eriksen C; von Heymann C
    Eur J Anaesthesiol; 2024 May; 41(5):327-350. PubMed ID: 38567679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of agents for reversing the effects of target-specific oral anticoagulants.
    Riley TR; Gauthier-Lewis ML; Sanchez CK; Douglas JS
    Am J Health Syst Pharm; 2017 Jan; 74(2):54-61. PubMed ID: 27895055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series.
    Morton C; Lista A; Jakowenko N; Salazar E; Donahue KR
    J Thromb Thrombolysis; 2022 Jan; 53(1):235-239. PubMed ID: 34236614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement and reversal of the direct oral anticoagulants.
    Samuelson BT; Cuker A
    Blood Rev; 2017 Jan; 31(1):77-84. PubMed ID: 27625113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct oral anticoagulants (DOAC) - Management of emergency situations.
    Lindhoff-Last E
    Hamostaseologie; 2017; 37(4):257-266. PubMed ID: 29582928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing the perioperative patient on direct oral anticoagulants.
    Leitch J; van Vlymen J
    Can J Anaesth; 2017 Jun; 64(6):656-672. PubMed ID: 28429198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.